echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sihuan Pharmaceutical's Class 1 new drug CDK4/6 inhibitor approved for Phase III clinical treatment of breast cancer

    Sihuan Pharmaceutical's Class 1 new drug CDK4/6 inhibitor approved for Phase III clinical treatment of breast cancer

    • Last Update: 2021-08-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    On August 12, Sihuan Biological issued an announcement stating that its subsidiary Xuanzhu Biological's application for a phase III clinical trial of Pirosinil (Birociclib, XZP-3287), a class 1 innovative drug under development, was approved by the China Food and Drug Administration


    Breast cancer is one of the highest incidence of malignant tumors in the world.


    The results of the clinical phase I study showed that as a new structure of CDK4/6 inhibitor, Pirosinib is expected to overcome the resistance problem of endocrine therapy in HR+ breast cancer patients; at the same time, Pirosinib is a single agent for advanced breasts that have failed multi-line therapy.


    At present, there are 3 domestic companies that have approved the listing of CDK4/6 inhibitor drugs, namely Eli Lilly, Pfizer and Qilu Pharmaceuticals


    Source: PharmaGo

    In 2020, the annual sales of CDK4/6 products on the market will exceed 7 billion U.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.